Serum uric acid as a marker of all-cause mortality in an elderly patients cohort;Utilidad del ácido úrico como marcador de mortalidad global en una cohorte de ancianos

Nefrologia

Volumn 32, Issue 1, 2012, Pages 67-72

  Heras, Manuel ^a   Fernández Reyes, María J ^a   Sánchez, Rosa ^a   Molina, Álvaro ^a   Rodríguez, Astrid ^a   Álvarez Ude, Fernando ^a  

^a HOSPITAL GENERAL DE SEGOVIA   (Spain)

Author keywords

Chronic kidney disease; Elderly; Glomerular filtration rate; Mortality; Serum uric acid

Indexed keywords

BIOLOGICAL MARKER; URIC ACID;

AGED; ARTICLE; BLOOD; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; COHORT ANALYSIS; FEMALE; HUMAN; KIDNEY DISEASE; MALE; MORTALITY; PROSPECTIVE STUDY;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; COHORT STUDIES; FEMALE; HUMANS; KIDNEY DISEASES; MALE; PROSPECTIVE STUDIES; URIC ACID;

EID: 84858405554     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: 10.3265/Nefrologia.pre2011.Nov.11021     Document Type: Article

References (25)

1. Oda M, Satta Y, Takenaka O, Takahata N. Loss of urate oxidase activity in hominoids and its evolutionary implications. Mol Biol Evol 2002;19(5):640-653.
2. Minguela JI, Hernando A, Gallardo I, Martínez I, García P, Muñoz RI, et al. La hiperuricemia como factor de riesgo cardiovascular y renal. Dial Transp 2011;32(2):57-61.
3. Johnson RJ, Kang D-H, Feig D, Kivlighn S, Kanellis J, Watanabe S, et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease. Hypertension 2003;41:1183-90.
4. So A, Thorens B. Uric Acid transport and disease. J Clin Invest 2010;120(6):1791-9.
5. Perlstein TS, Gumieniak O, Williams GH, Sparrow D, Vokonas PS, Gaziano M, et al. Uric acid and the development of hypertension: the normative aging study. Hypertension 2006;48(6):1031-6.
6. Waring WS, Webb DJ, Maxwell SRJ. Effect of local hyperuricemia on endothelial function in the human forearm vascular bed. Br J Clin Pharmacol 2000;49:511.
7. Obermayr RP, Temml C, Gutjahr G, Knechtelsdorfer M, Oberbauer R, Klauser-Braun R. Elevated uric acid increase the risk for kidney disease. J Am Soc Nephrol 2008;19:2407-13.
8. Ben-Dov IZ, Kark JD. Serum uric acid is a GFR-independent longterm predictor of acute and chronic renal insufficiency: the Jerusalem Lipid Research Clinic cohort study. Nephrol Dial Transplant 2011;26(8):2558-66.
9. Madero M, Sarnak MJ, Wang X, Greene T, Beck GJ, Kusek JW, et al. Uric acid and long term outcomes in CKD. Am J Kidney Dis 2009;53(5):796-803.
10. Heras M, Guerrero MT, Fernández-Reyes MJ, Sánchez R, Muñoz A, Macías MC, et al. Las manifestaciones analíticas asociadas a la insuficiencia renal crónica: ¿a partir de qué grado de filtrado glomerular las detectamos en ancianos? Rev Esp Geriatr Gerontol 2009;44(3):143-45.
11. Heras M, Fernández-Reyes MJ, Guerrero MT, Sánchez R, Muñoz A, Macias MC, et al. Ancianos con enfermedad renal crónica: ¿qué ocurre a los 24 meses de seguimiento? Nefrología 2009;4:343-9.
12. Heras M, Fernández-Reyes MJ, Guerrero MT, Sánchez R, Molina A, Rodríguez A, et al. Seguimiento durante 36 meses de la función renal en el anciano. Dial Transp 2011;32(3):97-101.
13. Levey AS, Greene T, Kusek JW, Beck GJ. Simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol 2000;11:828(A).
14. Galvan AQ, Natali A, Baldi S, Frascerra S, Sanna G, Ciociaro D, et al. Effect of insulin on uric acid excretion in humans. Am J Physiol 1995;268:E1-E5.
15. Nakagawa T, Mazzali M, Kang DH, Kanellis J, Watanabe S, Sánchez-Lozada LG, et al. Hyperuricemia causes glomerular hypertrophy in the rat. Am J Nephrol 2003;23:2-7.
16. Heras M, Fernández-Reyes MJ, Sánchez R, Guerrero MT, Prado F, Alvarez-Ude F. Repercusión sobre la función renal de los fármacos antihipertensivos utilizados en ancianos con hipertensión arterial esencial. Hipertensión 2008;25(5):194-7.
17. Elsayed N, Nakashima J, Postlethwait E. Measurement of uric acid as a marker of oxigen tension in the lung. Arch Biochem Biophys 1993;302:228-32.
18. Woolliscroft JO, Colfer H, Fox IH. Hyperuricemia in acute illness: a poor prognostic sign. Am J Med 1982;72:58-62.
19. Leyva F, Anker S, Swan JW, Godsland IF, Wingrove CS, Chua TP, et al. Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure. Eur Heart J 1997;18:858-65.
20. Franse LV, Pahor M, Di Bari M, Shorr RI, Wan JY, Somes G, et al. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program. J Hypertens 2000;18:1149-54.
21. Tabayashi K, Suzuki Y, Nagamine S, Ito Y, Sekino Y, Mohri H. A clinical trial of allopurinol (Zyloric) for myocardial protection. J Thorac Cardiovasc Surg 1991;101:713-18.
22. Goicoechea M, García de Vinuesa S, Verdalles V, Ruiz-Caro C, Ampuero J, Rincón A, et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol 2010;5:1388-93.
23. Bruce SP. Febuxostat: a selective xanthine oxidase inhibitor for the treatment of hyperuricemia and gout. Ann Pharmacother 2006;40:2187-94.
24. García de Vinuesa S. Factores de progresión de la enfermedad renal crónica. Prevención secundaria. Nefrologia 2008;S3:17-21.
25. Agrawal V, Marinescu V, Agarwal M, Mc Cullough. Cardiovascular implications of proteinuria: an indicator of chronic kidney disease. Nat Rev Cardiol 2009;6(4):301-11.